{
    "data": [
        {
            "id": "4644336",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-27T06:11:42-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1435498034/image_1435498034.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences Q3: Clinical Trial Updates Impress",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107127",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "496794",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4644336-edwards-lifesciences-stock-q3-earnings-clinical-trial-updates-impress-reiterate-buy"
            }
        },
        {
            "id": "4644053",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-26T17:21:03-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1330421995/image_1330421995.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "496767",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4644053-for-edwards-lifesciences-sector-derating-seems-like-a-bigger-threat-than-competition-or-slowing-markets"
            }
        },
        {
            "id": "4629953",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-21T07:01:11-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1404179486/image_1404179486.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences: Rising Dominance In Structural Heart Disease",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107127",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "478959",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4629953-edwards-lifesciences-rising-dominance-instructural-heart-disease"
            }
        },
        {
            "id": "4611099",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-12T23:39:04-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1410025200/image_1410025200.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences: Slowly Approaching Its Intrinsic Value",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "462959",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4611099-edwards-lifesciences-stock-slowly-approaching-intrinsic-value"
            }
        },
        {
            "id": "4611048",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-12T17:55:23-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413603540/image_1413603540.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences: Valuation Seems Still Too Elevated",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106586",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "462673",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4611048-edwards-lifesciences-valuation-seems-still-too-elevated"
            }
        },
        {
            "id": "4610978",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-12T13:42:19-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1472546101/image_1472546101.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences: Valuation Premium Earned, But Shares Are Not Cheap, Technicals Mixed",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106553",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "462916",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4610978-edwards-lifesciences-valuation-premium-earned-but-shares-not-cheap-technicals-mixed"
            }
        },
        {
            "id": "4591296",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-30T13:24:06-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303850380/image_1303850380.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Where Will Edwards Lifesciences Stock Be In 4 Years?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95006",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "447163",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4591296-where-will-edwards-lifesciences-stock-be-in-4-years"
            }
        },
        {
            "id": "4590742",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-28T17:33:35-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413031831/image_1413031831.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences: Solid, Not Spectacular",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "446796",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4590742-edwards-lifesciences-solid-not-spectacular"
            }
        },
        {
            "id": "4575427",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-05T03:05:00-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/645512052/image_645512052.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Wedgewood Partners - Edwards Lifesciences: Tremendous Returns Despite High Future Growth Reinvestments",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105080",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4575427-edwards-lifesciences-stock-tremendous-returns-despite-high-future-growth-reinvestments"
            }
        },
        {
            "id": "4570530",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-18T04:17:56-05:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/973136992/image_973136992.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences: Short-Term Growth Worries Have Created An Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106204",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "431894",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4570530-edwards-lifesciences-short-term-growth-worries-have-created-an-opportunity"
            }
        }
    ]
}